MaltSci 麦伴科研

Appearance

Popular Reports / Cancer Research

This report is written by MaltSci based on the latest literature and research findings

What is the role of cancer stem cells in tumor recurrence? ​

Abstract ​

Cancer remains a leading cause of morbidity and mortality worldwide, with tumor recurrence presenting a significant challenge in effective cancer management. A growing body of evidence indicates that cancer stem cells (CSCs) play a crucial role in this phenomenon. CSCs are a distinct subset of tumor cells characterized by their self-renewal and differentiation capabilities, contributing to tumor heterogeneity and complexity. They are associated with therapeutic resistance, as conventional treatments often fail to eradicate these resilient cells, leading to disease relapse and progression. This review explores the multifaceted role of CSCs in tumor recurrence, focusing on their contributions to therapeutic resistance, metastasis, and interactions within the tumor microenvironment. Mechanistic insights reveal that signaling pathways such as Wnt, Notch, and Hedgehog are pivotal for CSC maintenance and their tumorigenic potential. The review also discusses the implications for treatment strategies, including current clinical trials targeting CSCs and potential future directions. By understanding the biology of CSCs, novel therapeutic interventions can be developed to enhance treatment efficacy and improve patient outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Characteristics of Cancer Stem Cells
    • 2.1 Definition and Identification of CSCs
    • 2.2 Unique Properties of CSCs
  • 3 Mechanisms of Tumor Recurrence
    • 3.1 CSCs and Therapeutic Resistance
    • 3.2 Role of the Tumor Microenvironment
  • 4 Molecular Pathways Involved in CSC Maintenance
    • 4.1 Signaling Pathways (e.g., Wnt, Notch, Hedgehog)
    • 4.2 Genetic and Epigenetic Regulation
  • 5 Implications for Treatment Strategies
    • 5.1 Targeting CSCs in Cancer Therapy
    • 5.2 Clinical Trials and Future Directions
  • 6 Challenges and Future Perspectives
    • 6.1 Limitations of Current Research
    • 6.2 Potential for Novel Therapeutic Approaches
  • 7 Conclusion

1 Introduction ​

Cancer remains one of the leading causes of morbidity and mortality worldwide, with tumor recurrence being a significant challenge in effective cancer management. A growing body of evidence suggests that a subset of tumor cells known as cancer stem cells (CSCs) plays a pivotal role in this phenomenon. Unlike their differentiated counterparts, CSCs possess unique properties such as self-renewal and the ability to differentiate into various cell types, contributing to tumor heterogeneity and complexity [1][2]. This review aims to elucidate the multifaceted role of CSCs in tumor recurrence, focusing on their contributions to therapeutic resistance, metastasis, and interactions within the tumor microenvironment.

The significance of understanding CSCs in the context of tumor recurrence cannot be overstated. Conventional therapies, including chemotherapy and radiation, often fail to eradicate these resilient cells, leading to disease relapse and progression [3][4]. Research indicates that CSCs are inherently resistant to standard treatments, a characteristic that complicates therapeutic strategies and contributes to poor patient outcomes [2][5]. Moreover, the unique interactions between CSCs and their microenvironment facilitate their survival and proliferation, creating a supportive niche that further complicates treatment efficacy [6][7].

Current research has made significant strides in identifying the mechanisms underlying CSC maintenance and their role in tumor recurrence. Studies have highlighted various molecular pathways, including Wnt, Notch, and Hedgehog signaling, which are critical for CSC self-renewal and differentiation [5][8]. Additionally, genetic and epigenetic modifications within CSCs contribute to their tumorigenic potential and therapeutic resistance [9][10]. Understanding these mechanisms not only provides insights into tumor biology but also opens avenues for novel therapeutic interventions aimed at targeting CSCs.

The organization of this review is structured to provide a comprehensive overview of the current understanding of CSCs and their role in tumor recurrence. The first section will define and identify CSCs, followed by a discussion of their unique properties. The mechanisms by which CSCs contribute to tumor recurrence will be explored, with a focus on therapeutic resistance and the tumor microenvironment. Subsequently, we will examine the molecular pathways involved in CSC maintenance, emphasizing the significance of signaling pathways and genetic regulation. The implications for treatment strategies will be discussed, including current clinical trials targeting CSCs and potential future directions. Finally, we will address the challenges and limitations of current research, outlining the need for innovative therapeutic approaches to effectively combat tumor recurrence.

In conclusion, understanding the biology of CSCs is crucial for developing more effective cancer treatments and improving patient outcomes. By delving into the complexities of CSCs and their role in tumor recurrence, this review aims to contribute to the ongoing discourse in cancer research and facilitate the development of targeted therapies that can enhance the efficacy of existing treatment modalities.

2 Characteristics of Cancer Stem Cells ​

2.1 Definition and Identification of CSCs ​

Cancer stem cells (CSCs) are a distinct subpopulation of tumor cells that exhibit unique characteristics crucial to tumor recurrence. They are defined by their capacity for self-renewal and differentiation, akin to normal stem cells, which allows them to sustain tumor growth and contribute to the heterogeneity of cancer. CSCs are responsible for tumor initiation, progression, and metastasis, and their persistence is often linked to treatment failure and disease relapse.

The role of CSCs in tumor recurrence is underscored by their ability to evade conventional therapies, including chemotherapy and radiation. Standard cancer treatments often target rapidly dividing cells, which can lead to the selective survival of CSCs that may possess inherent resistance mechanisms. These mechanisms include enhanced DNA repair capabilities, altered drug efflux through ATP-binding cassette (ABC) transporters, and the activation of developmental signaling pathways such as Wnt, Notch, and Hedgehog, which are known to promote self-renewal and stemness characteristics in CSCs [11].

Furthermore, CSCs have been shown to reside in specific niches within the tumor microenvironment that support their survival and maintenance. These niches provide a protective microenvironment that facilitates their quiescence and resistance to therapeutic agents [10]. The interplay between CSCs and their microenvironment is pivotal, as factors such as hypoxia, cytokines, and extracellular matrix components can influence CSC behavior and contribute to their ability to reinitiate tumor growth after therapy [7].

Identification of CSCs typically involves the use of specific surface markers and functional assays. For instance, various markers such as CD44, CD24, and ALDH have been employed to isolate and characterize CSC populations in different tumor types [2]. These markers help distinguish CSCs from more differentiated tumor cells, which are generally less tumorigenic and do not exhibit the same capacity for self-renewal.

In summary, cancer stem cells play a critical role in tumor recurrence due to their unique characteristics of self-renewal, resistance to therapies, and ability to thrive in supportive microenvironments. Their identification and understanding are essential for developing targeted therapies aimed at eradicating these cells, thereby improving patient outcomes and reducing the likelihood of relapse [1][2][3].

2.2 Unique Properties of CSCs ​

Cancer stem cells (CSCs) are a distinct subpopulation of tumor cells characterized by their ability to self-renew and differentiate into various cell types within the tumor. This unique capacity is central to their role in tumor recurrence. CSCs contribute significantly to the sustained growth of malignant tumors and are implicated in resistance to standard treatments, leading to challenges in achieving long-term remission for cancer patients.

One of the defining features of CSCs is their potential for infinite proliferation. They are not only responsible for initiating and maintaining tumor growth but also play a crucial role in the recurrence of tumors after treatment. This recurrence can often be attributed to the ability of CSCs to survive conventional therapies such as chemotherapy and radiation, which typically target the more differentiated tumor cells but fail to eliminate the CSCs themselves (Dingli and Michor, 2006; Alhasan et al., 2023).

CSCs exhibit several unique properties that distinguish them from their differentiated counterparts. They possess enhanced capabilities for self-renewal and differentiation, akin to normal stem cells, which allows them to regenerate the tumor mass after therapy. Furthermore, CSCs can evade apoptosis and resist cytotoxic agents due to various mechanisms, including increased DNA repair capacity and the expression of drug efflux transporters (Ischenko et al., 2008; Bajaj et al., 2020). This resistance not only contributes to treatment failure but also facilitates tumor metastasis and the emergence of more aggressive tumor phenotypes.

The tumor microenvironment (TME) also plays a significant role in the behavior of CSCs. Factors within the TME can influence the dormancy and activation of CSCs, thereby impacting tumor recurrence. For instance, tumor-associated macrophages (TAMs) can secrete cytokines that promote CSC survival and transition from a dormant state to active proliferation (Zhang et al., 2025). This interplay between CSCs and the TME is crucial for understanding the mechanisms behind tumor recurrence and developing targeted therapies.

In summary, CSCs are pivotal in tumor recurrence due to their unique properties, including self-renewal, resistance to therapies, and interactions with the TME. Targeting these cells may provide a promising avenue for improving cancer treatment outcomes and reducing the likelihood of recurrence (Miyoshi et al., 2021; Wang et al., 2021). By focusing on the elimination of CSCs, it may be possible to enhance the effectiveness of existing therapies and achieve more durable responses in cancer patients.

3 Mechanisms of Tumor Recurrence ​

3.1 CSCs and Therapeutic Resistance ​

Cancer stem cells (CSCs) play a pivotal role in tumor recurrence, primarily due to their unique characteristics that confer resistance to conventional therapies. CSCs are a subset of cancer cells with the ability to self-renew and differentiate, similar to normal stem cells, which allows them to regenerate tumors after treatment. Their presence is associated with therapy resistance, leading to tumor relapse and metastasis.

One of the fundamental mechanisms by which CSCs contribute to tumor recurrence is their inherent resistance to chemotherapy and radiation therapy. Studies have shown that CSCs exhibit higher expression of ATP-binding cassette (ABC) membrane transporters, which actively efflux therapeutic agents, thereby reducing drug efficacy [12]. Additionally, CSCs demonstrate enhanced epithelial to mesenchymal transition (EMT) characteristics, which facilitate their migration and invasion, further complicating treatment efforts [13].

The tumor microenvironment also plays a crucial role in the maintenance and survival of CSCs. Factors secreted by surrounding cells, such as fibroblasts, can induce a state of "stemness" in differentiated tumor cells, allowing them to acquire CSC-like properties and resistance to therapies [14]. This plasticity enables tumors to adapt to therapeutic pressures, resulting in the emergence of resistant populations that can lead to recurrence.

Moreover, signaling pathways involved in stem cell maintenance, such as Notch, Wnt, and Hedgehog, are often activated in CSCs, contributing to their self-renewal and survival [15]. The activation of these pathways not only supports CSC persistence but also enhances their ability to withstand therapeutic interventions.

The molecular mechanisms underlying CSCs' resistance include alterations in apoptotic pathways and the expression of specific markers associated with drug resistance. For instance, high levels of HMGA2 have been implicated in promoting drug resistance in CSCs, highlighting the importance of understanding these molecular interactions to develop more effective therapeutic strategies [13].

Furthermore, recent advances in immunotherapy have revealed that CSCs express unique tumor-associated antigens, making them attractive targets for novel therapeutic approaches. By selectively targeting CSCs with immunotherapies, there is potential to overcome the challenges posed by their resistance and contribute to more durable treatment responses [6].

In summary, the role of cancer stem cells in tumor recurrence is multifaceted, involving their unique characteristics that promote survival and resistance to therapies, as well as their ability to adapt and regenerate tumors in response to treatment. Addressing these challenges requires a comprehensive understanding of CSC biology and the development of targeted therapies aimed at eradicating these resilient cell populations to improve patient outcomes.

3.2 Role of the Tumor Microenvironment ​

Cancer stem cells (CSCs) play a pivotal role in tumor recurrence, significantly influencing the mechanisms behind this phenomenon. Tumor recurrence often arises from a small population of CSCs that can enter a dormant state, persist in this quiescent condition, and subsequently transition back to proliferation. This behavior is characteristic of various cell types, including cancer stem cells, tumor-initiating cells, disseminated tumor cells, and drug-tolerant persisters, all of which exhibit similar properties that contribute to the complexity of tumor recurrence [16].

The tumor microenvironment is crucial in regulating the behavior of CSCs, particularly their quiescence and reawakening. Interactions between CSCs and the tumor microenvironment are dynamic and can evolve over time, significantly impacting cancer cell characteristics such as stemness and proliferation [17]. The microenvironment provides essential signals that can either promote dormancy or trigger reactivation, thus influencing the fate of CSCs. This interplay is vital for understanding how dormant CSCs can evade therapeutic interventions and contribute to tumor relapse [18].

Additionally, various signaling pathways within the tumor microenvironment, including TGF-β, WNT, and HIPPO, have been identified as key regulators of the proliferation-dormancy switch in CSCs. These pathways modulate the expression of critical cell cycle regulators, thereby governing the transition between dormancy and active proliferation [7]. The presence of tumor-associated macrophages (TAMs) within the microenvironment further complicates this relationship. TAMs can secrete cytokines and engage in direct cellular interactions with tumor cells, influencing their fate and contributing to the dormancy and reawakening processes [7].

The role of CSCs in tumor recurrence is further underscored by their inherent resistance to conventional therapies, which often fail to target these cells effectively. Standard treatments may reduce the bulk of the tumor but are less effective against the CSC population, which can lead to treatment failure and recurrence [3]. Therefore, understanding the mechanisms that regulate CSCs and their interactions with the tumor microenvironment is crucial for developing new therapeutic strategies aimed at preventing tumor recurrence and improving patient outcomes [19].

In summary, cancer stem cells are central to the process of tumor recurrence, with their behavior intricately linked to the tumor microenvironment. The ability of CSCs to enter a dormant state, evade therapy, and later reactivate underscores the complexity of cancer management and highlights the need for targeted approaches that address these resilient cell populations.

4 Molecular Pathways Involved in CSC Maintenance ​

4.1 Signaling Pathways (e.g., Wnt, Notch, Hedgehog) ​

Cancer stem cells (CSCs) play a pivotal role in tumor recurrence due to their unique properties, which include self-renewal, differentiation into various tumor cell types, and inherent resistance to conventional therapies. The presence of CSCs in tumors is a significant factor contributing to tumor initiation, growth, and the eventual relapse of cancer after treatment. This is primarily because CSCs can evade the effects of chemotherapy and radiotherapy, leading to a resurgence of the tumor after initial treatment success.

The maintenance of CSCs is closely associated with the dysregulation of several key signaling pathways, particularly the Wnt, Notch, and Hedgehog pathways. These pathways are evolutionarily conserved and play critical roles in normal embryonic development, but their aberrant activation in cancer is linked to the promotion of CSC characteristics and tumor progression.

The Wnt signaling pathway is crucial for the maintenance of stemness in CSCs. It regulates various cellular processes, including cell proliferation and differentiation. Dysregulated Wnt signaling has been implicated in promoting tumorigenesis and enhancing the stem-like properties of cancer cells, which facilitates their survival and proliferation in adverse conditions, thereby contributing to tumor recurrence[20][21].

Similarly, the Notch signaling pathway is involved in maintaining the self-renewal capacity of CSCs. Notch signaling can function as both an oncogenic factor and a tumor suppressor, depending on the context. In many tumors, Notch signaling is found to be upregulated, which supports the proliferation and maintenance of CSCs. This pathway's ability to influence cell fate decisions is critical for the preservation of the CSC population, which can lead to tumor relapse after therapy[22][23].

The Hedgehog signaling pathway also plays a significant role in CSC biology. It has been shown to be essential for the proliferation of glioma-initiating cells and is involved in various malignancies. Inhibition of Hedgehog signaling has been linked to the reduction of CSC populations and subsequent tumor growth inhibition. However, resistance to therapies targeting this pathway can arise, complicating treatment strategies[24][25].

In summary, the interplay of the Wnt, Notch, and Hedgehog signaling pathways is fundamental to the maintenance and function of cancer stem cells. Their dysregulation not only supports the aggressive nature of tumors but also contributes to the challenges of achieving long-term remission in cancer patients. Consequently, targeting these pathways presents a promising avenue for developing novel therapeutic strategies aimed at eradicating CSCs and preventing tumor recurrence[21][26][27].

4.2 Genetic and Epigenetic Regulation ​

Cancer stem cells (CSCs) play a pivotal role in tumor recurrence, primarily due to their unique properties that confer self-renewal, differentiation, and resistance to conventional therapies. The presence of CSCs within tumors contributes significantly to tumor heterogeneity, which complicates treatment efforts and is a key factor in the recurrence of cancer following therapy.

The cancer stem cell model posits that a small subset of cells within a tumor, characterized by stem-like properties, is responsible for driving tumor initiation, progression, and metastasis. These cells possess the ability to self-renew and differentiate into various cell types that comprise the tumor, thus sustaining tumor growth and contributing to its heterogeneous nature (Sundar et al. 2014). The intratumoral phenotypic and molecular heterogeneity is not only a hallmark of glioblastoma but also a feature observed in many other malignancies, where CSCs are recognized as critical for tumor propagation and treatment resistance (Kumar et al. 2022).

The mechanisms underlying CSC maintenance and tumor recurrence are closely linked to genetic and epigenetic regulation. Epigenetic modifications, such as DNA methylation and histone modifications, play a crucial role in regulating gene expression patterns that are vital for CSC survival and function (Keyvani-Ghamsari et al. 2021). These modifications can lead to the activation of oncogenes and silencing of tumor suppressor genes, thereby enhancing the tumorigenic potential of CSCs (van Vlerken et al. 2012). Moreover, epigenetic dysregulation has been shown to impact pathways involved in cell proliferation, survival, and metastasis, contributing to the CSC phenotype and the resultant therapy resistance (Toh et al. 2017).

Current research highlights the importance of targeting epigenetic modulators as a therapeutic strategy to eliminate CSCs and prevent tumor recurrence. By focusing on the epigenetic landscape that governs CSC behavior, new treatment regimens are being developed to enhance the efficacy of existing therapies and address the challenges posed by CSCs in cancer treatment (Kaleem et al. 2025). This approach aims to disrupt the pathways that maintain CSCs, thereby reducing their capacity to regenerate tumors post-therapy (Hubert et al. 2023).

In summary, the role of cancer stem cells in tumor recurrence is underscored by their inherent properties that promote tumor survival and heterogeneity. The interplay of genetic and epigenetic mechanisms is crucial for maintaining CSC populations, which ultimately contributes to the challenges faced in achieving long-term remission in cancer patients. Targeting these pathways represents a promising avenue for developing more effective cancer therapies aimed at eradicating CSCs and preventing recurrence.

5 Implications for Treatment Strategies ​

5.1 Targeting CSCs in Cancer Therapy ​

Cancer stem cells (CSCs) are increasingly recognized as critical players in tumor recurrence and the development of resistance to conventional therapies. Their unique properties, including self-renewal and differentiation, allow them to survive treatments that typically target the bulk of the tumor, leading to relapse and metastasis.

CSCs contribute to tumor recurrence through several mechanisms. Firstly, they possess the ability to evade standard therapies, such as chemotherapy and radiation, which primarily target rapidly dividing cells. Studies have shown that CSCs can be enriched following treatment with agents like doxorubicin and cisplatin, indicating their potential to survive and repopulate the tumor after therapy (Martins-Neves et al. 2018). This phenomenon is attributed to their intrinsic characteristics, such as increased expression of drug efflux pumps and activation of survival pathways, including Notch, Hedgehog, and Wnt signaling (Martins-Neves et al. 2018).

Furthermore, CSCs exhibit phenotypic plasticity, which enables them to transition between differentiated and stem-like states in response to environmental cues, particularly during therapy (Aldoghachi et al. 2023). This plasticity not only facilitates their survival but also allows for the re-initiation of tumor growth post-treatment, underscoring the importance of targeting these cells in therapeutic strategies.

To effectively address the challenge posed by CSCs, treatment strategies must be multifaceted. Traditional therapies need to be combined with approaches specifically aimed at eradicating CSCs. This could involve the use of differentiation therapy, immunotherapy targeting CSC-specific antigens, or agents that inhibit the signaling pathways crucial for CSC maintenance and survival (Wang et al. 2021). For instance, novel immunotherapies that selectively target CSCs have shown promise, as these cells often express unique tumor-associated antigens that can be exploited for therapeutic gain (Wang et al. 2021).

Moreover, the identification and quantification of CSCs using specific markers can enhance the precision of cancer therapies, allowing for tailored treatment plans that account for the presence of these resilient cells (Miyoshi et al. 2021). The development of novel techniques for targeting CSCs, including reprogramming strategies and the use of exosomal microRNAs for non-cell-based therapies, presents exciting avenues for improving treatment outcomes (Aldoghachi et al. 2023).

In conclusion, targeting cancer stem cells is imperative for effective cancer therapy. Their role in tumor recurrence and resistance highlights the need for integrated treatment approaches that not only aim to reduce tumor bulk but also specifically eradicate the CSC population to prevent relapse and improve patient prognosis (Dingli and Michor 2006; Aldoghachi et al. 2023).

5.2 Clinical Trials and Future Directions ​

Cancer stem cells (CSCs) are increasingly recognized as a critical factor in tumor recurrence, contributing significantly to the challenges faced in effective cancer treatment. Their unique properties, including self-renewal and the ability to differentiate into various cell types, make them a key player in the persistence and re-emergence of tumors after treatment.

CSCs are thought to be responsible for the recurrence of tumors due to their inherent resistance to conventional therapies such as chemotherapy and radiation. This resistance can arise from several mechanisms, including enhanced DNA repair capabilities, activation of drug efflux pumps, and the ability to enter a quiescent state that allows them to evade the cytotoxic effects of treatments [11]. For instance, studies have shown that CSCs can be enriched following treatment with chemotherapeutic agents, which may lead to a phenotypic transition from differentiated cells to a stem-like state, thereby contributing to tumor relapse [15].

The implications for treatment strategies are profound. To effectively target and eliminate tumors, it is essential to develop therapeutic approaches that specifically address CSCs. This includes strategies that combine traditional therapies with agents designed to target the unique signaling pathways active in CSCs, such as the Notch, Wnt, and Hedgehog pathways [28]. Moreover, immunotherapy has emerged as a promising avenue for targeting CSCs due to their expression of specific tumor-associated antigens [6]. These therapies may enhance the efficacy of existing treatments by sensitizing CSCs to conventional therapies or directly targeting them.

Clinical trials are increasingly focused on evaluating the effectiveness of CSC-targeted therapies. For example, trials exploring the use of agents that inhibit CSC pathways or employ immune-based strategies are being designed to assess their potential in reducing tumor recurrence and improving overall survival rates [29]. The integration of CSC-targeting strategies into clinical practice is crucial, as it could lead to more durable responses and potentially cure patients who are currently considered refractory to standard treatments.

Future directions in this field include a deeper understanding of the biological characteristics of CSCs and their interactions within the tumor microenvironment. This knowledge will facilitate the identification of novel biomarkers for CSCs, which can be utilized for patient stratification in clinical trials and personalized treatment approaches [30]. Additionally, ongoing research into the role of non-coding RNAs and exosomal signaling in CSC biology may unveil new therapeutic targets and strategies to combat tumor recurrence [28].

In summary, the role of cancer stem cells in tumor recurrence underscores the necessity for innovative treatment strategies that specifically target these cells. As research progresses, the development of effective therapies aimed at eradicating CSCs may provide significant improvements in cancer treatment outcomes and the prevention of recurrence.

6 Challenges and Future Perspectives ​

6.1 Limitations of Current Research ​

Cancer stem cells (CSCs) play a significant role in tumor recurrence, primarily due to their unique properties that enable them to survive conventional therapies and contribute to tumor regeneration. The existence of CSCs has been postulated to explain why some tumors recur after seemingly successful treatment, as these cells exhibit characteristics akin to normal stem cells, such as self-renewal and differentiation capabilities.

Research indicates that CSCs are often resistant to chemotherapy and radiation, which allows them to persist in the tumor microenvironment despite the eradication of differentiated tumor cells. For instance, it has been reported that as few as 0.1% of the tumor mass may consist of these chemoresistant and radioresistant cells, which possess stem-like properties that drive tumor survival, development, and metastasis (Patel et al., 2010) [31]. The intrinsic or acquired resistance of tumor cells to standard therapies is a major clinical challenge, leading to local recurrence and metastatic disease (Martins-Neves et al., 2018) [15].

The phenotypic plasticity of CSCs allows them to transition from a differentiated state to a stem-like state, which is associated with the activation of various self-renewal pathways (e.g., Notch, Hedgehog, Wnt) and survival pathways (e.g., TGF-β, ERK, AKT) (Martins-Neves et al., 2018) [15]. This transition is critical for understanding how CSCs contribute to therapeutic failures and subsequent tumor recurrence. Furthermore, the tumor microenvironment plays a crucial role in supporting CSCs, with various factors influencing their behavior and survival (Patel et al., 2010) [31].

Despite the advancements in understanding CSCs, significant limitations remain in current research. For instance, while the cancer stem cell hypothesis has gained substantial support, controversies still exist regarding the origins and characterization of these cells. Moreover, the complexity of tumor heterogeneity poses challenges in isolating and targeting CSCs effectively (Lathia et al., 2011) [32]. There is also a lack of successful targeted therapies that have reached clinical application, which indicates a need for further research to unravel the underlying mechanisms of CSCs and their role in tumor recurrence (Dingli and Michor, 2006) [3].

In summary, cancer stem cells are integral to the phenomenon of tumor recurrence due to their resistance to conventional therapies and their ability to regenerate tumors. However, the current understanding of CSCs is limited by ongoing debates about their nature, challenges in targeting them effectively, and the complex interplay with the tumor microenvironment. Addressing these limitations is crucial for developing effective therapeutic strategies aimed at eradicating CSCs and preventing tumor recurrence.

6.2 Potential for Novel Therapeutic Approaches ​

Cancer stem cells (CSCs) play a critical role in tumor recurrence, drug resistance, and overall cancer progression. These cells possess unique characteristics that enable them to evade conventional therapies, leading to challenges in effective cancer treatment. CSCs are defined by their ability to self-renew and differentiate, which contributes to their role in maintaining tumor heterogeneity and facilitating tumor growth. They are often resistant to standard therapies such as chemotherapy and radiotherapy, which primarily target rapidly dividing cells, leaving the CSC population intact and capable of reinitiating tumor growth after treatment.

The phenomenon of tumor recurrence is frequently attributed to the presence of CSCs, which can survive therapeutic interventions due to their inherent properties. According to Wang et al. (2021), CSCs are central to tumor recurrence and the development of drug resistance, making them important targets in cancer immunotherapy. These cells express novel tumor-associated antigens that arise from mutations during treatment, highlighting their unique biological characteristics that differ from the bulk tumor cells [6].

Dingli and Michor (2006) emphasize that successful cancer therapy must eradicate tumor stem cells, as their persistence is a major contributor to treatment failure and subsequent tumor recurrence [3]. This assertion is supported by the observation that standard therapies do not effectively target CSCs, which are responsible for sustaining tumor growth and driving relapse [3]. Moreover, Martins-Neves et al. (2018) discuss how therapy-induced enrichment of CSCs occurs in response to conventional treatments, suggesting that these therapies can inadvertently select for CSC populations that are more resistant to future interventions [15].

The implications of targeting CSCs for therapeutic approaches are significant. Natural products have been identified as potential agents for targeting CSCs, as they may modulate various signaling pathways associated with CSC self-renewal, such as the Wnt, Notch, and Hedgehog pathways [33]. Such strategies aim to not only eliminate CSCs but also to enhance the efficacy of existing treatments by overcoming resistance mechanisms.

Future perspectives in CSC research involve the exploration of combined therapeutic strategies that simultaneously target both drug-sensitive tumor cells and the CSC population. This approach may help to prevent tumor recurrence and improve patient outcomes. Additionally, the potential for utilizing stem cells in cancer therapy, as highlighted by Aldoghachi et al. (2023), indicates that understanding the interactions between different stem cell types and the tumor microenvironment could yield innovative therapeutic strategies [28].

In conclusion, cancer stem cells are pivotal in tumor recurrence and drug resistance, posing significant challenges in cancer treatment. However, they also represent a promising target for novel therapeutic approaches that could enhance treatment efficacy and reduce the likelihood of recurrence. As research progresses, a deeper understanding of CSC biology and their interactions within the tumor microenvironment will be essential for developing effective strategies to combat cancer.

7 Conclusion ​

Cancer stem cells (CSCs) are central to the challenges of tumor recurrence and therapeutic resistance in cancer management. Their unique properties, including self-renewal and differentiation, enable them to survive conventional therapies, leading to treatment failures and disease relapse. The current understanding of CSCs emphasizes their role in tumor initiation, maintenance, and the complexity of tumor heterogeneity. Research highlights the importance of the tumor microenvironment in supporting CSCs and influencing their behavior, particularly in relation to dormancy and reactivation. Despite advancements in identifying the mechanisms underlying CSC biology, significant limitations remain, including controversies regarding their characterization and the challenges in effectively targeting these cells. Future research must focus on innovative therapeutic strategies that specifically target CSCs while addressing the interactions within the tumor microenvironment. By overcoming these challenges, it may be possible to develop more effective treatments that improve patient outcomes and reduce the likelihood of tumor recurrence.

References ​

  • [1] Elodie Terrié;Valérie Coronas;Bruno Constantin. Role of the calcium toolkit in cancer stem cells.. Cell calcium(IF=4.0). 2019. PMID:31103948. DOI: 10.1016/j.ceca.2019.05.001.
  • [2] Mojdeh Safari;Alireza Khoshnevisan. An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.. World journal of stem cells(IF=3.6). 2014. PMID:24567788. DOI: 10.4252/wjsc.v6.i1.53.
  • [3] David Dingli;Franziska Michor. Successful therapy must eradicate cancer stem cells.. Stem cells (Dayton, Ohio)(IF=3.6). 2006. PMID:16931775. DOI: 10.1634/stemcells.2006-0136.
  • [4] Thomas W Owens;Matthew J Naylor. Breast cancer stem cells.. Frontiers in physiology(IF=3.4). 2013. PMID:23986719. DOI: 10.3389/fphys.2013.00225.
  • [5] Jennie Powell Mather. In vitro models.. Stem cells (Dayton, Ohio)(IF=3.6). 2012. PMID:22076915. DOI: 10.1002/stem.774.
  • [6] Wenjun Wang;Ling Bai;Dongsheng Xu;Wei Li;Jiuwei Cui. Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.. Current cancer drug targets(IF=3.5). 2021. PMID:32364076. DOI: 10.2174/1568009620666200504111914.
  • [7] Hongxing Zhang;Yiyue Ding;Lihui Gu;Ai Guo;Wanli Duan;Xuejie Wang;Baogang Zhang. Macrophage regulation of tumor cell dormancy and the dormant niche: an overview in solid tumors.. Cancer metastasis reviews(IF=8.7). 2025. PMID:40762813. DOI: 10.1007/s10555-025-10280-4.
  • [8] Jeevisha Bajaj;Emily Diaz;Tannishtha Reya. Stem cells in cancer initiation and progression.. The Journal of cell biology(IF=6.4). 2020. PMID:31874116. DOI: 10.1083/jcb.201911053.
  • [9] Dan Liu;Hong Li;Hui Dong;Mincheng Qu;Liguang Yang;Lina Chen;Yixue Li;Hongyang Wang;Yufei He. Spatial Multiomics Analysis Reveals Only Minor Genetic and Epigenetic Changes in Human Liver Cancer Stem-Like Cells Compared With Other Tumor Parenchymal Cells.. Frontiers in cell and developmental biology(IF=4.3). 2022. PMID:35223840. DOI: 10.3389/fcell.2022.810687.
  • [10] Yasemin Ceyhan;Nina Marie G Garcia;James V Alvarez. Immune cells in residual disease and recurrence.. Trends in cancer(IF=17.5). 2023. PMID:37150627. DOI: 10.1016/j.trecan.2023.04.001.
  • [11] Ivan Ischenko;Hendrik Seeliger;Moshe Schaffer;Karl-Walter Jauch;Christiane J Bruns. Cancer stem cells: how can we target them?. Current medicinal chemistry(IF=3.5). 2008. PMID:19075661. DOI: 10.2174/092986708786848541.
  • [12] Naurin Fatima;Mohammad Umar;Subiya Ambreen;Mohammad Shaququzzaman;Mohammad Mumtaz Alam;Ruhi Ali. Targeted Cancer Stem Cell Therapeutics: An Update.. Current topics in medicinal chemistry(IF=3.3). 2025. PMID:38288804. DOI: 10.2174/0115680266275014240110071351.
  • [13] Huldani Huldani;Saade Abdalkareem Jasim;Klunko Nataliya Sergeenva;Dmitry Olegovich Bokov;Walid Kamal Abdelbasset;Rustam Turakulov;Moaed E Al-Gazally;Behnam Ahmadzadeh;Zanko Hassan Jawhar;Homayoon Siahmansouri. Mechanisms of cancer stem cells drug resistance and the pivotal role of HMGA2.. Pathology, research and practice(IF=3.2). 2022. PMID:35468338. DOI: 10.1016/j.prp.2022.153906.
  • [14] S Colak;J P Medema. Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells.. Cell cycle (Georgetown, Tex.)(IF=3.4). 2016. PMID:25483065. DOI: 10.4161/15384101.2014.973321.
  • [15] Sara R Martins-Neves;Anne-Marie Cleton-Jansen;Célia M F Gomes. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?. Pharmacological research(IF=10.5). 2018. PMID:30316903. DOI: 10.1016/j.phrs.2018.10.011.
  • [16] Bashar Alhasan;Marina Mikeladze;Irina Guzhova;Boris Margulis. Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence.. Cancer metastasis reviews(IF=8.7). 2023. PMID:36723697. DOI: 10.1007/s10555-023-10085-3.
  • [17] Antonella Sistigu;Martina Musella;Claudia Galassi;Ilio Vitale;Ruggero De Maria. Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.. Frontiers in immunology(IF=5.9). 2020. PMID:33193295. DOI: 10.3389/fimmu.2020.02166.
  • [18] Bashar A Alhasan;Alexey V Morozov;Irina V Guzhova;Boris A Margulis. The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence.. Biochimica et biophysica acta. Reviews on cancer(IF=8.3). 2024. PMID:38761982. DOI: 10.1016/j.bbcan.2024.189119.
  • [19] Jose Adan Gutierrez-Cruz;Vilma Maldonado;Jorge Melendez-Zajgla. Regulation of the Cancer Stem Phenotype by Long Non-Coding RNAs.. Cells(IF=5.2). 2022. PMID:35954194. DOI: 10.3390/cells11152352.
  • [20] Jeffrey Koury;Li Zhong;Jijun Hao. Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment.. Stem cells international(IF=3.3). 2017. PMID:28356914. DOI: 10.1155/2017/2925869.
  • [21] Subhasmita Bhal;Chanakya Nath Kundu. Targeting crosstalk of signaling pathways in cancer stem cells: a promising approach for development of novel anti-cancer therapeutics.. Medical oncology (Northwood, London, England)(IF=3.5). 2023. PMID:36662310. DOI: 10.1007/s12032-022-01905-7.
  • [22] Christian T Meisel;Cristina Porcheri;Thimios A Mitsiadis. Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression.. Cells(IF=5.2). 2020. PMID:32796631. DOI: 10.3390/cells9081879.
  • [23] Qingmiao Shi;Chen Xue;Yifan Zeng;Xin Yuan;Qingfei Chu;Shuwen Jiang;Jinzhi Wang;Yaqi Zhang;Danhua Zhu;Lanjuan Li. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.. Signal transduction and targeted therapy(IF=52.7). 2024. PMID:38797752. DOI: 10.1038/s41392-024-01828-x.
  • [24] Tatsuya Takezaki;Takuichiro Hide;Hiromi Takanaga;Hideo Nakamura;Jun-Ichi Kuratsu;Toru Kondo. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells.. Cancer science(IF=4.3). 2011. PMID:21453386. DOI: 10.1111/j.1349-7006.2011.01943.x.
  • [25] Sabina Iluta;Madalina Nistor;Sanda Buruiana;Delia Dima. Notch and Hedgehog Signaling Unveiled: Crosstalk, Roles, and Breakthroughs in Cancer Stem Cell Research.. Life (Basel, Switzerland)(IF=3.4). 2025. PMID:40003637. DOI: 10.3390/life15020228.
  • [26] Sharmistha Chatterjee;Parames C Sil. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy.. Pharmacological research(IF=10.5). 2019. PMID:30826456. DOI: 10.1016/j.phrs.2019.02.027.
  • [27] Gillian A Horne;Mhairi Copland. Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.. Expert opinion on drug discovery(IF=4.9). 2017. PMID:28277836. DOI: 10.1080/17460441.2017.1303477.
  • [28] Ahmed Faris Aldoghachi;Zhi Xiong Chong;Swee Keong Yeap;Soon Keng Cheong;Wan Yong Ho;Alan Han Kiat Ong. Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy.. International journal of molecular sciences(IF=4.9). 2023. PMID:36674525. DOI: 10.3390/ijms24021012.
  • [29] Laurence Haddadin;Xueqin Sun. Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies.. Cells(IF=5.2). 2025. PMID:40214491. DOI: 10.3390/cells14070538.
  • [30] Marius Eugen Ciurea;Ada Maria Georgescu;Stefana Oana Purcaru;Stefan-Alexandru Artene;Ghazaleh Hooshyar Emami;Mihai Virgil Boldeanu;Daniela Elise Tache;Anica Dricu. Cancer stem cells: biological functions and therapeutically targeting.. International journal of molecular sciences(IF=4.9). 2014. PMID:24821540. DOI: 10.3390/ijms15058169.
  • [31] Shyam A Patel;Anicia Ndabahaliye;Philip K Lim;Russell Milton;Pranela Rameshwar. Challenges in the development of future treatments for breast cancer stem cells.. Breast cancer (Dove Medical Press)(IF=3.4). 2010. PMID:25114585. DOI: .
  • [32] Justin D Lathia;Monica Venere;Mahendra S Rao;Jeremy N Rich. Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology?. Stem cell reviews and reports(IF=4.2). 2011. PMID:20957452. DOI: 10.1007/s12015-010-9194-6.
  • [33] Kanchan Gairola;Shriya Gururani;Ananya Bahuguna;Vaishali Garia;Rohit Pujari;Shiv K Dubey. Natural products targeting cancer stem cells: Implications for cancer chemoprevention and therapeutics.. Journal of food biochemistry(IF=4.2). 2021. PMID:34028051. DOI: 10.1111/jfbc.13772.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

cancer stem cells · tumor recurrence · therapeutic resistance · tumor microenvironment

© 2025 MaltSci